These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 2115096)

  • 21. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?
    Phillips KA; Hotlgrave DR
    Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Threshold values for cost-effectiveness ratio and public funding of medical technologies].
    Rabinovich M; Greenberg D; Shemer J
    Harefuah; 2007 Jun; 146(6):453-8, 500. PubMed ID: 17760400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations.
    Nixon RM; Thompson SG
    Health Econ; 2005 Dec; 14(12):1217-29. PubMed ID: 15945043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness in healthcare: complexity of the equation.
    Archambault A
    J Can Diet Assoc; 1988; 49(2):80-5. PubMed ID: 10312528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subgroup analyses in cost-effectiveness analyses to support health technology assessments.
    Fletcher C; Chuang-Stein C; Paget MA; Reid C; Hawkins N
    Pharm Stat; 2014; 13(4):265-74. PubMed ID: 24931490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis.
    Stinnett AA; Mullahy J
    Med Decis Making; 1998; 18(2 Suppl):S68-80. PubMed ID: 9566468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing cost-effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible?
    Mullins CD; Blak BT; Akhras KS
    Value Health; 2002; 5(4):359-71. PubMed ID: 12102698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
    Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
    J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness acceptability curves--caveats quantified.
    Jakubczyk M; Kamiński B
    Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout.
    Meltzer M; Pizzi LT; Jutkowitz E
    Evid Based Med; 2012 Aug; 17(4):105-8. PubMed ID: 22345034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women.
    Kwon JS; Lu KH
    Obstet Gynecol; 2008 Jul; 112(1):56-63. PubMed ID: 18591308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost analyses approaches in medical education: there are no simple solutions.
    Walsh K; Levin H; Jaye P; Gazzard J
    Med Educ; 2013 Oct; 47(10):962-8. PubMed ID: 24016166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Methodology of economic assessment: example in oncology].
    Jaisson-Hot I; Schott AM; Clippe C; Ganne C; Hajri T; Poncet B; Trillet-Lenoir V; Colin C
    Bull Cancer; 2003 Nov; 90(11):939-45. PubMed ID: 14706896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A proposed cost effectiveness method for use in policy formulation in human service organizations.
    Holosko MJ; Dobrowolsky J; Feit MD
    J Health Soc Policy; 1990; 1(3):55-71. PubMed ID: 10113664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dollar is a dollar is a dollar--or is it?
    Brouwer WB; van Exel NJ; Baltussen RM; Rutten FF
    Value Health; 2006; 9(5):341-7. PubMed ID: 16961552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probabilistic sensitivity analysis in cost-effectiveness. An application from a study of vaccination against pneumococcal bacteremia in the elderly.
    Whang W; Sisk JE; Heitjan DF; Moskowitz AJ
    Int J Technol Assess Health Care; 1999; 15(3):563-72. PubMed ID: 10874382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant.
    Dowie J
    Health Econ; 2004 May; 13(5):453-9. PubMed ID: 15127425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using cost-effectiveness analysis in policy formulation in human service organizations.
    Holosko MJ; Dobrowolsky J; Feit MD
    J Health Soc Policy; 1989; 1(1):43-60. PubMed ID: 10313498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Getting the cost right in cost-effectiveness analyses.
    Wolff N; Helminiak TW; Tebes JK
    Am J Psychiatry; 1997 Jun; 154(6):736-43. PubMed ID: 9167499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sample size and power for cost-effectiveness analysis (Part 2): the effect of maximum willingness to pay.
    Glick HA
    Pharmacoeconomics; 2011 Apr; 29(4):287-96. PubMed ID: 21395349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.